Log in
E-mail
Password
Show password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON
  1. Homepage
  2. Equities
  3. Japan
  4. Japan Exchange
  5. Japan Lifeline Co., Ltd.
  6. News
  7. Summary
    7575   JP3754500001

JAPAN LIFELINE CO., LTD.

(7575)
  Report
SummaryChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
SummaryMost relevantAll NewsOther languagesPress ReleasesOfficial PublicationsSector news

Japan Lifeline : Notice on Acquisition of Shares of Sub-subsidiary

09/30/2021 | 02:12am EST

September 30, 2021

To whom it may concern,

Company: Japan Lifeline Co., Ltd.

Representative: Keisuke Suzuki, President and CEO (Code: 7575 TSE 1st Section)

Contact person: Kenji Yamada, Senior Vice President, Corporate Administration Headquarters (TEL. +81-3-6711-5200)

Notice on Acquisition of Shares of Sub-subsidiary

Japan Lifeline Co., Ltd. (the Company) announced that at the Board of Directors meeting held today, it has resolved to acquire shares of Synexmed(Shenzhen) Co., Ltd., a wholly owned subsidiary of Synexmed(Hong Kong) Limited, which is a wholly owned subsidiary of the Company.

1. Reason for the Share Acquisition

Synexmed(Shenzhen) Co., Ltd. is a Company's overseas manufacturing base for its proprietary products, and the purpose of this share acquisition is to improve the efficiency of the management of the corporate group as a whole by directly holding the shares of the said company.

2. Outline of the Acquired Company

1.

Company Name

Synexmed(Shenzchen) Co., Ltd.

2.

Location

Shenzchen, Guangdong Province, China

3.

Representative Officer

Shogo Takahashi (Chairman)

4.

Business Description

Manufacturing and sales of medical devices

5.

Capital

2.5 million USD (279 million JPY*1

6.

Date of Establishment

March 30, 2005

7.

Major Shareholders and their

Synexmed(Hong Kong) Limited100%

Shareholding Ratio

Capital

The Company indirectly owns 100% of the shares of

Relationship

this company.

8.

Relationship with the

Personal

Two officers of the Company concurrently serve as

Company

Relationship

officers of the said company.

Business

The Company indirectly receives supply of products

Relationship

from the said company.

*1 The yen conversion rate of the capital is based on the foreign exchange rate for customers provided by MUFG Bank, Ltd. as of September 29, 2021 (1 USD = 111.65JPY (TTM)) (Figures are rounded down to the nearest million yen)

1

3. Outline of the counterparty to the share acquisition

1.

Company Name

Synexmed(Hong Kong) Limited

2.

Location

Hong Kong

3.

Representative Officer

Shogo Takahashi (Managing Director)

4.

Business Description

Import and sales of medical devices

5.

Capital

15 million Hong Kong dollars (218 million JPY)※2

6.

Date of Establishment

December 17, 2004

7.

Major Shareholder and their

Japan Lifeline Co., Ltd100%

Shareholding Ratio

Capital

The Company owns 100% of the shares of this

Relationship

company.

8.

Relationship with the

Personal

Two officers of the Company concurrently serve as

Company

Relationship

officers of the said company.

Business

The Company receives supply of products from the

Relationship

said company.

*2 The yen conversion rate of the capital is based on the foreign exchange rate for customers provided by MUFG Bank, Ltd. as of September 29, 2021 (1 HKD = 14.34 JPY (TTM)) (Figures are rounded down to the nearest million yen)

4. Schedule

1.

Resolution by the Board of

September 30, 2021

Directors

2.

Date of Conclusion of Share

September 30, 2021

Transfer Agreement

3.

Execution Date of Share

October 8, 2021(Scheduled)

Transfer

5. Impact on Business Result

As this share acquisition is an intra-group transaction, the impact on the Company's consolidated business results will be minimal.

2

Disclaimer

JLL - Japan Lifeline Co. Ltd. published this content on 30 September 2021 and is solely responsible for the information contained therein. Distributed by Public, unedited and unaltered, on 30 September 2021 06:11:10 UTC.


ę Publicnow 2021
All news about JAPAN LIFELINE CO., LTD.
11/01Japan Lifeline Co., Ltd. Announces Changes in Organizations and Personnel
CI
11/01Japan Lifeline Co., Ltd. Provides Dividend Guidance for the Year Ending March 31, 2022
CI
11/01Japan Lifeline Co., Ltd. Provides Earnings Guidance for the Year Ending March 31, 2022
CI
09/30JAPAN LIFELINE : Notice on Acquisition of Shares of Sub-subsidiary
PU
09/30JAPAN LIFELINE : Notice on Board Resolution on Selection for TSE's New Prime Market Segmen..
PU
09/02Japan Lifeline Co., Ltd. Announces Changes in Organizations, Effective on October 1, 20..
CI
09/02Japan Lifeline Co., Ltd. Announces Changes in Personnel, Effective on October 1, 2021
CI
08/04JAPAN LIFELINE : Summary Report of Consolidated Financial Results for the Three Months End..
PU
08/04Japan Lifeline Co., Ltd. Provides Year End Cash Dividend Guidance for the Year Ending M..
CI
08/04Japan Lifeline Co., Ltd. Provides Earnings Guidance for the Six Months Ending September..
CI
More news
Financials
Sales 2022 52 886 M 465 M 465 M
Net income 2022 7 882 M 69,3 M 69,3 M
Net cash 2022 7 581 M 66,7 M 66,7 M
P/E ratio 2022 11,2x
Yield 2022 3,36%
Capitalization 88 221 M 778 M 776 M
EV / Sales 2022 1,52x
EV / Sales 2023 1,33x
Nbr of Employees 1 167
Free-Float 68,2%
Chart JAPAN LIFELINE CO., LTD.
Duration : Period :
Japan Lifeline Co., Ltd. Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends JAPAN LIFELINE CO., LTD.
Short TermMid-TermLong Term
TrendsBearishBearishBearish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 6
Last Close Price 1 097,00 JPY
Average target price 1 583,33 JPY
Spread / Average Target 44,3%
EPS Revisions
Managers and Directors
Keisuke Suzuki President & Representative Director
Takeshi Egawa Manager-Accounting & Finance
Yumiko Hoshiba Director & Senior Manager-Personnel
Kenji Yamada MD, GM-Administration & Head-Corporate Planning
Fumihiro Sasaki Independent Outside Director
Sector and Competitors